Stoke Therapeutics Adds Rare Disease Veteran to Board Amid Phase 3 Push
Event summary
- Stoke Therapeutics appointed Clare Kahn, Ph.D., to its Board of Directors on April 7, 2026.
- Kahn brings 30+ years of experience in rare disease drug development, including roles at Pfizer and GlaxoSmithKline.
- Stoke's lead candidate, zorevunersen, is in Phase 3 trials for Dravet syndrome, a severe epileptic encephalopathy.
- Zorevunersen has received FDA Breakthrough Therapy and rare pediatric disease designations.
- Biogen holds exclusive commercialization rights outside the U.S., Canada, and Mexico under a strategic collaboration.
The big picture
Stoke's appointment of Clare Kahn underscores its focus on navigating complex regulatory pathways for rare disease therapies. The move comes as RNA medicine gains traction in neurological indications, with zorevunersen positioned as a potential first-in-class treatment. The Biogen partnership expands Stoke's commercial reach, though execution risks remain high in this competitive therapeutic landscape.
What we're watching
- Regulatory Momentum
- Whether zorevunersen's Breakthrough Therapy designation will accelerate FDA review and approval.
- Clinical Execution
- The pace at which Phase 3 trial results for zorevunersen could reshape Dravet syndrome treatment.
- Commercial Strategy
- How Biogen's global commercialization strategy will impact zorevunersen's market penetration outside North America.
Related topics